ANCA ASSOCIATED VASCULITIS
Clinical trials for ANCA ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANCA ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANCA ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy targets Hard-to-Treat autoimmune diseases
Disease control TerminatedThis early-stage study is testing the safety and initial effects of a new cell therapy called RD06-04 for people with active, severe autoimmune diseases. The therapy involves modifying a patient's own immune cells (CAR-T cells) to target and remove certain harmful immune cells. T…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 22:56 UTC
-
Scientists test 'Living Drug' to reset immune system in 8 serious diseases
Disease control TerminatedThis early-phase study aimed to test a new type of cell therapy for people with serious autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis. The therapy, called CAR-T, involves modifying a patient's own immune cells to target and remove the cells causing the…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Scientists test 'Living Drug' to reset the immune system in devastating autoimmune conditions
Disease control OngoingThis early-stage study is testing the safety and initial effects of a personalized cell therapy called KYV-101 in adults with severe autoimmune diseases. The therapy involves collecting a patient's own immune cells, modifying them to target harmful B cells, and reinfusing them. U…
Matched conditions: ANCA ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: David Porter • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC